Sign in

What researchers published on Macular degeneration

13,668 papers, newest first.

Showing 20 of 651

  • Trial resultFirst-in-Human Regulatory T Cell-Derived Exosomes Plus Ranibizumab for Refractory nAMD.Journal of extracellular vesicles
  • Randomised trialThe Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial.Translational vision science & technology
  • Randomised trialEffect of a mobile application-based whole-course nutrition management intervention in patients with age-related macular degeneration: a randomized controlled trial.Frontiers in public health
  • Randomised trialShort-term adjunctive use of a liposomal tear substitute after repeated intravitreal therapy: a randomized pilot study.International ophthalmology
  • Randomised trialLongitudinal Prediction of Retinal Sensitivity Based on Disease Progression Quantified From Optical Coherence Tomography in Geographic Atrophy.Investigative ophthalmology & visual science
  • Randomised trialCost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial.American journal of ophthalmology
  • Randomised trialIncomplete Retinal Pigment Epithelium and Outer Retinal Atrophy Characterized Using Fundus Autofluorescence: An 18-Month Post Hoc Analysis of GATHER2.Investigative ophthalmology & visual science
  • Randomised trialEQ-5D vision bolt-on in macular degeneration: associations with visual measures and effect on utility differences and cost-effectiveness of stereotactic radiotherapy.Health and quality of life outcomes
  • Trial resultArtificial Intelligence-Assisted Screening for Patients With Diabetic Retinopathy and Age-Related Macular Degeneration in Family Medicine and Geriatric and Gerontology Care: Protocol for a Pragmatic Randomized Clinical Trial.JMIR research protocols
  • Randomised trialEffect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension: A Post Hoc 96-Week Analysis of PULSAR.Ophthalmology. Retina
  • Randomised trialAvacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy.Ophthalmology
  • Randomised trialStereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR).BMJ (Clinical research ed.)
  • Randomised trialCommunity Optometrist-Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE Randomized Clinical Trial.JAMA network open
  • Trial resultSubretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.Cell reports. Medicine
  • Randomised trialGildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial.Ophthalmology. Retina
  • Trial resultWT1-pulsed dendritic cell vaccination for neovascular age-related macular degeneration: a phase I pilot feasibility study.BMC ophthalmology
  • Trial resultI-SCREEN: Development of an AI-based infrastructure for community-wide screening and prediction of progression in age-related macular degeneration providing accessible shared care.Eye (London, England)
  • Randomised trialVision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution.Ophthalmology
  • Randomised trialAssociation between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration.Scientific reports
  • Randomised trialPULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics.Ophthalmology. Retina